Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Traffic & App Usage Insights

Discover domain traffic and app usage trends for companies and their competitors.

MRUS

Merus N.V

Oct 04 • 04:00PM ET

51.78

Dollar change +1.92
Percentage change 3.85	%

Healthcare • Biotechnology • Netherlands • NASD

Held by: IBB VHT SPDW SBIO KOMP NUSC FYC FYX ESML FHLC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.87	Insider Own	13.17%	Shs Outstand	68.21M	Perf Week	8.46%
Market Cap	3.53B	Forward P/E	-	EPS next Y	-3.67	Insider Trans	-1.01%	Shs Float	59.23M	Perf Month	2.80%
Income	-167.66M	PEG	-	EPS next Q	-0.87	Inst Own	88.44%	Short Float	12.01%	Perf Quarter	-7.05%
Sales	35.19M	P/S	100.37	EPS this Y	-2.71%	Inst Trans	33.95%	Short Ratio	12.79	Perf Half Y	15.84%
Book/sh	11.01	P/B	4.70	EPS next Y	-19.00%	ROA	-26.70%	Short Interest	7.11M	Perf Year	144.48%
Cash/sh	11.54	P/C	4.49	EPS next 5Y	-8.20%	ROE	-33.39%	52W Range	19.81 - 61.61	Perf YTD	88.29%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-18.50%	ROI	-22.17%	52W High	-15.96%	Beta	1.12
Dividend TTM	-	Quick Ratio	9.97	Sales past 5Y	7.00%	Gross Margin	-	52W Low	161.45%	ATR (14)	1.67
Dividend Ex-Date	-	Current Ratio	9.97	EPS Y/Y TTM	24.98%	Oper. Margin	-560.03%	RSI (14)	58.17	Volatility	3.41% 3.36%
Employees	229	Debt/Eq	0.01	Sales Y/Y TTM	-14.63%	Profit Margin	-476.41%	Recom	1.00	Target Price	89.07
Option/Short	Yes / Yes	LT Debt/Eq	0.01	EPS Q/Q	-22.05%	Payout	-	Rel Volume	0.46	Prev Close	49.86
Sales Surprise	-15.88%	EPS Surprise	-6.65%	Sales Q/Q	-30.01%	Earnings	Aug 01 AMC	Avg Volume	555.82K	Price	51.78
SMA20	4.83%	SMA50	1.60%	SMA200	11.83%	Trades		Volume	257,050	Change	3.85%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-28-24	Initiated	Truist	Buy	$69
Mar-04-24	Reiterated	Needham	Buy	$42 → $65
Nov-02-23	Initiated	Canaccord Genuity	Buy	$45
Aug-21-23	Initiated	TD Cowen	Outperform
Aug-02-22	Initiated	Stifel	Buy	$38
Feb-11-22	Initiated	BMO Capital Markets	Outperform	$45
Feb-10-22	Initiated	Needham	Buy	$45
Nov-17-21	Resumed	Guggenheim	Buy	$44
Jun-07-21	Upgrade	Citigroup	Neutral → Buy	$24 → $31
Apr-08-21	Initiated	William Blair	Outperform
Mar-16-21	Initiated	SVB Leerink	Outperform	$33
Jun-26-20	Initiated	H.C. Wainwright	Buy	$23
May-27-20	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$16
Nov-20-19	Resumed	Guggenheim	Buy
Jun-28-19	Initiated	ROTH Capital	Buy	$20
Apr-12-19	Resumed	Guggenheim	Buy
Apr-03-19	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Mar-27-19	Initiated	Berenberg	Buy	$35
Jan-02-18	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Sep-15-17	Initiated	RBC Capital Mkts	Outperform	$28

Show Previous Ratings

Sep-30-24 08:00AM	Merus Announces First Patient Dosed in LiGeR-HN1, a Phase 3 Trial Evaluating Petosemtamab in Combination with Pembrolizumab in 1L r/m HNSCC (GlobeNewswire)
Sep-18-24 10:11AM	TimesSquare Capital Management U.S. Small Cap Growth Strategy Established a Position in Merus N.V. (MRUS) (Insider Monkey)
Sep-17-24 09:00AM	Merus Announces Abstract Accepted for Presentation at the ESMO Asia Congress 2024 (GlobeNewswire)
Sep-14-24 05:15PM	Merus NV (MRUS): Short Seller Sentiment is Bearish on This Cancer Stock (Insider Monkey)
Aug-30-24 01:15AM	Merus NV (MRUS): Top ADR Stock According to Hedge Funds (Insider Monkey)
04:37PM	Loading…
Aug-12-24 04:37PM	Biotech Innovations: Revolutionary Treatments Aim to Boost Pancreatic Cancer Survival Rates (PR Newswire)
Aug-06-24 08:00AM	Merus to Present at Canaccord Genuity's 44th Annual Growth Conference (GlobeNewswire)
Aug-01-24 05:30PM	Merus N.V. (MRUS) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:10PM	Merus Announces Financial Results for the Second Quarter 2024 and Provides Business Update (GlobeNewswire)
Jul-29-24 10:00AM	Merus N.V. (MRUS) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Jul-24-24 07:00AM	Merus Announces First Patient Dosed in LiGeR-HN2, a Phase 3 Trial Evaluating Petosemtamab in 2/3L r/m HNSCC (GlobeNewswire)
Jul-08-24 08:00AM	Merus Announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 2L CRC (GlobeNewswire)
Jul-01-24 08:00AM	Merus Appoints Fabian Zohren M.D., Ph.D., as Chief Medical Officer (GlobeNewswire) -7.98%
Jun-03-24 02:30PM	Merus' MCLA-129 Demonstrates Promising Single-Agent Efficiency in METex14 NSCLC in Poster Presentation at the 2024 ASCO Annual Meeting (GlobeNewswire)
Jun-02-24 12:30PM	Merus Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab at the 2024 ASCO Annual Meeting (GlobeNewswire)
09:30PM	Loading…
May-29-24 09:30PM	Merus Announces Pricing of Upsized Public Offering of Common Shares (GlobeNewswire) +6.11%
08:00AM	Merus to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-28-24 04:01PM	Merus N.V. Announces Proposed Public Offering of Common Shares (GlobeNewswire) -8.53%
07:00AM	Merus' Petosemtamab in Combination with Pembrolizumab Interim Data Demonstrates Robust Response Rate and Favorable Safety Profile in 1L r/m HNSCC (GlobeNewswire)
May-27-24 11:37AM	Merus (MRUS) Surges 36% on Head & Neck Cancer Antibody Data (Zacks)
May-24-24 04:05PM	Why Top 4% Biotech Stock, Merus, Just Catapulted To A Record High (Investor's Business Daily) +36.12% -8.53%
03:41PM	Why Is Cancer-Focused Merus Stock Trading Over 30% On Friday? (Benzinga)
01:31PM	Merus Clears Wall Street's Bar With Cancer Data (Barrons.com)
12:00PM	Cancer Biotech Stocks Are on the Move Ahead of a Big Event. What to Know. (Barrons.com)
08:47AM	ASCO 2024: Merus touts positive Phase II data for head and neck cancer antibody (Pharmaceutical Technology)
07:16AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace)
07:01AM	ASCO: Early peek at Merus' bispecific cancer data lives up to investors' expectations (FierceBiotech.com)
May-23-24 05:00PM	Merus Announces Publication of an Abstract on Petosemtamab with Pembrolizumab as 1L treatment of r/m HNSCC at the 2024 ASCO Annual Meeting (GlobeNewswire)
05:00PM	Merus Announces Publication of Abstracts for Presentation at the 2024 ASCO Annual Meeting (GlobeNewswire)
11:51AM	Pancreatic Cancer Battle Intensifies: Biotech Innovations Aim to Boost Survival Rates (PR Newswire)
12:50PM	Loading…
May-17-24 12:50PM	Early Detection Breakthrough: Biotech Companies Lead the Way in Pancreatic Cancer Treatment (PR Newswire)
May-13-24 09:58AM	Merus Says US FDA Grants Breakthrough Therapy Designation for Petosemtamab (MT Newswires)
08:00AM	Petosemtamab granted Breakthrough Therapy Designation by the U.S. FDA (GlobeNewswire)
May-09-24 12:53AM	MRUS Stock Earnings: Merus Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
May-08-24 04:15PM	Merus Announces Financial Results for the First Quarter 2024 and Provides Business Update (GlobeNewswire)
May-06-24 04:05PM	Merus Announces U.S. FDA Acceptance and Priority Review of Biologics License Application for Zeno for the Treatment of NRG1+ NSCLC and PDAC (GlobeNewswire)
Apr-26-24 07:58AM	Merus (MRUS) Moves 7.1% Higher: Will This Strength Last? (Zacks)
Apr-25-24 10:01AM	Will Merus N.V. (MRUS) Report Negative Q1 Earnings? What You Should Know (Zacks) +7.05%
Apr-24-24 10:00AM	Merus Announces Abstracts Accepted for Presentation at the 2024 ASCO Annual Meeting (GlobeNewswire)
Apr-08-24 12:00PM	Merus Presents Preclinical Data Demonstrating Efficacy of Zeno in Cancer Models with High NRG1 Expression at the AACR Annual Meeting 2024 (GlobeNewswire)
Apr-03-24 08:00AM	Merus to Participate in a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-06-24 10:11AM	Gilead tries new triple-target T-cell engagers in $1.5B-plus Merus collab (FierceBiotech.com)
08:00AM	Gilead and Merus Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell Engagers (Business Wire)
06:15AM	Gilead bets on trispecifics in latest cancer drug deal (BioPharma Dive)
Mar-05-24 04:30PM	Merus Announces Publication of an Abstract for Presentation at the AACR Annual Meeting 2024: Zeno is effective in cancer models with high NRG1 expression (GlobeNewswire)
Mar-04-24 08:00AM	Merus to Participate in a Fireside Chat at the Leerink Partners Global Biopharma Conference (GlobeNewswire)
Feb-28-24 04:15PM	Merus Announces Financial Results for the Fourth Quarter and Full Year 2023 and Provides Business Update (GlobeNewswire)
Feb-20-24 10:00AM	Merus N.V. (MRUS) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Feb-16-24 03:57AM	15 Top Performing European Stocks So Far in 2024 (Insider Monkey) +5.89%
Jan-31-24 08:00AM	Merus to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-09-24 05:07AM	Merus N.V. (MRUS) Surges 16.3%: Is This an Indication of Further Gains? (Zacks)
Dec-28-23 09:55AM	Wall Street Analysts See a 52.96% Upside in Merus N.V. (MRUS): Can the Stock Really Move This High? (Zacks)
Dec-12-23 09:55AM	Wall Street Analysts Think Merus N.V. (MRUS) Could Surge 87.71%: Read This Before Placing a Bet (Zacks)
Dec-05-23 12:00PM	Merus N.V. (MRUS) Moves to Buy: Rationale Behind the Upgrade (Zacks)
Dec-04-23 12:15PM	Merus shares dip as interim lung cancer data reveal 3 patient deaths (FierceBiotech.com) -6.13%
Dec-02-23 08:40PM	Merus Presents Interim Data on MCLA-129 at ESMO Asia Congress 2023 (GlobeNewswire)
Nov-26-23 11:05AM	Merus Announces Publication of Abstracts on MCLA-129 for Presentation at ESMO Asia Congress 2023 (GlobeNewswire)
Nov-23-23 09:55AM	Wall Street Analysts See an 85.36% Upside in Merus N.V. (MRUS): Can the Stock Really Move This High? (Zacks)
Nov-07-23 09:55AM	Wall Street Analysts Think Merus N.V. (MRUS) Could Surge 83.26%: Read This Before Placing a Bet (Zacks)
Nov-02-23 04:12PM	Merus Announces Financial Results for the Third Quarter 2023 and Provides Business Update (GlobeNewswire) +5.53% +13.40%
Nov-01-23 08:00AM	Merus to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-31-23 10:01AM	ADC Therapeutics SA (ADCT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Oct-26-23 10:02AM	Merus N.V. (MRUS) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Oct-23-23 07:30AM	Merus' Zeno Interim Data Continues to Demonstrate Robust and Durable Responses in NRG1+ Cancer (GlobeNewswire)
Oct-17-23 05:00AM	Merus N.V. (MRUS) Soars 5.5%: Is Further Upside Left in the Stock? (Zacks)
Oct-15-23 07:58PM	Merus Announces Business Update Conference Call (GlobeNewswire)
Oct-13-23 09:00AM	New FDA Designations Accelerate Progress in Pancreatic Cancer Treatments: A Year in Review (PR Newswire)
Oct-06-23 09:32AM	Merus Announces Abstracts Accepted for Presentation at the ESMO Asia Congress 2023 (GlobeNewswire)
Sep-11-23 03:45AM	GSK (GSK) Moves 5.5% Higher: Will This Strength Last? (Zacks)
Sep-07-23 07:36PM	Merus NV (MRUS): A Deep Dive into Its Overvalued Status (GuruFocus.com)
Aug-31-23 08:00AM	Merus to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-21-23 09:44AM	XPeng upgraded, Napco downgraded: Wall Street's top analyst calls (The Fly)
Aug-09-23 09:53PM	Merus Announces Pricing of Public Offering of Common Shares (GlobeNewswire)
04:01PM	Merus N.V. Announces Proposed Public Offering of Common Shares (GlobeNewswire)
Aug-07-23 07:15PM	Merus N.V. (MRUS) Reports Q2 Loss, Tops Revenue Estimates (Zacks) -8.34%
04:26PM	Merus Announces Financial Results for the Second Quarter 2023 and Provides Business Update (GlobeNewswire)
Jul-28-23 08:00AM	Merus Announces Two Clinical Abstracts on Zenocutuzumab (Zeno) in NRG1-fusion (NRG1+) non-small cell lung cancer (NSCLC) and Pancreatic Cancer (PDAC) Selected for Presentation at the ESMO Congress 2023 (GlobeNewswire)
Jul-05-23 04:01PM	Zenocutuzumab (Zeno) granted second Breakthrough Therapy Designation by the U.S. Food & Drug Administration (GlobeNewswire)
Jun-29-23 04:30PM	Zenocutuzumab (Zeno) granted Breakthrough Therapy Designation by the U.S. Food & Drug Administration for the treatment of NRG1+ pancreatic cancer (GlobeNewswire)
Jun-28-23 07:35AM	Institutional investors may overlook Merus N.V.'s (NASDAQ:MRUS) recent US$113m market cap drop as long-term gains remain positive (Simply Wall St.)
Jun-15-23 07:47AM	Merus Appoints Life Sciences Strategic and Financial Industry Veteran Greg Perry as Chief Financial Officer (GlobeNewswire)
May-31-23 08:00AM	Merus to Participate in a Fireside Chat at the Jefferies Healthcare Conference 2023 (GlobeNewswire)
May-21-23 03:28PM	7 Stocks That Wall Street Analysts Are Loving in May (InvestorPlace)
May-11-23 12:00PM	Here's Why Merus N.V. (MRUS) is a Great Momentum Stock to Buy (Zacks)
May-10-23 09:55AM	Wall Street Analysts Believe Merus N.V. (MRUS) Could Rally 114.58%: Here's is How to Trade (Zacks)
May-05-23 10:24AM	Some Confidence Is Lacking In Merus N.V.'s (NASDAQ:MRUS) P/S (Simply Wall St.) +10.58%
May-04-23 08:15PM	Merus N.V. (MRUS) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:25PM	Merus Announces Financial Results for the First Quarter 2023 and Provides Business Update (GlobeNewswire)
May-02-23 10:01AM	Bluebird Bio (BLUE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
May-01-23 10:00AM	Analysts Estimate Merus N.V. (MRUS) to Report a Decline in Earnings: What to Look Out for (Zacks)
Apr-17-23 10:15AM	Merus Petosemtamab Interim Data Demonstrates Clinically Meaningful Activity in Previously Treated Head and Neck Squamous Cell Carcinoma (HNSCC) (GlobeNewswire) +10.07%
Apr-14-23 11:10AM	Merus Announces Publication of an Abstract on Petosemtamab Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma for Plenary Session Oral Presentation at the AACR Annual Meeting 2023 and Provides a Program and Regulatory Update (GlobeNewswire) +11.42%
11:10AM	Merus Announces Publication of an Abstract on Petosemtamab in Advanced Gastric/Esophageal Adenocarcinoma for Presentation at the AACR Annual Meeting 2023 (GlobeNewswire)
Apr-10-23 10:16AM	Merus' (NASDAQ:MRUS) investors will be pleased with their respectable 53% return over the last three years (Simply Wall St.)
Mar-14-23 04:30PM	Merus Announces Publication of an Abstract on Preclinical Mechanism of Action of MCLA-129 Selected for Poster Presentation at the AACR Annual Meeting 2023 (GlobeNewswire) +8.74%
04:30PM	Merus Announces Petosemtamab in Previously Treated Head and Neck Squamous Cell Carcinoma Abstract Selected for Plenary Session Oral Presentation at the AACR Annual Meeting 2023 (GlobeNewswire)
09:08AM	We Think Merus (NASDAQ:MRUS) Needs To Drive Business Growth Carefully (Simply Wall St.)
Feb-28-23 04:25PM	Merus Announces Financial Results for the Fourth Quarter and Full Year 2022 and Provides Business Update (GlobeNewswire)
Feb-23-23 11:37AM	Is a Surprise Coming for Merus (MRUS) This Earnings Season? (Zacks)
Feb-20-23 10:00AM	Merus N.V. (MRUS) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)

Merus NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of bispecific antibody therapeutics. Its pipeline includes Biclonics for solid and hematological tumors. The company was founded by Ton Logtenberg and Hennie Hoogenboom on June 16, 2003 and is headquartered in Utrecht, the Netherlands.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Shuman Harry	VP Controller, PAO	Aug 21 '24	Sale	54.00	2,500	135,000	7,002	Aug 22 04:03 PM
Shuman Harry	VP Controller, PAO	Aug 20 '24	Sale	54.00	2,500	135,000	7,002	Aug 22 04:03 PM
Silverman Peter B.	COO & GC	Jun 27 '24	Option Exercise	17.94	10,000	179,400	10,000	Jun 28 04:05 PM
Silverman Peter B.	COO & GC	Jun 27 '24	Sale	60.00	10,000	600,000	0	Jun 28 04:05 PM
Silverman Peter B.	COO & GC	Jun 17 '24	Option Exercise	24.36	62,000	1,510,280	62,000	Jun 20 04:30 PM
Silverman Peter B.	COO & GC	Jun 17 '24	Sale	56.52	62,000	3,504,178	0	Jun 20 04:30 PM
Shuman Harry	VP Controller, PAO	Jun 12 '24	Sale	57.84	7,300	422,232	7,002	Jun 12 05:02 PM
Shuman Harry	VP Controller, PAO	Jun 10 '24	Sale	53.22	1,000	53,224	7,002	Jun 12 05:02 PM
Shuman Harry	VP Controller, PAO	Jun 04 '24	Sale	52.89	6,000	317,354	7,002	Jun 06 04:05 PM
Shuman Harry	VP Controller, PAO	Dec 19 '23	Sale	26.68	115	3,068	7,002	Dec 20 04:05 PM
Silverman Peter B.	COO & GC	Dec 15 '23	Sale	25.00	22,386	559,650	0	Dec 18 05:15 PM
Shuman Harry	VP Controller, PAO	Dec 08 '23	Sale	24.44	250	6,110	7,117	Dec 12 04:04 PM
Shuman Harry	VP Controller, PAO	Dec 01 '23	Option Exercise	0.00	2,500	0	7,942	Dec 04 04:05 PM
Shuman Harry	VP Controller, PAO	Dec 01 '23	Sale	24.58	575	14,133	7,367	Dec 04 04:05 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MRUS

Merus N.V

Upgrade your FINVIZ experience